OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE®

OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial 
Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients 
with Metastatic Pancreatic Cancer 
Pancreatic Cancer Becomes the Fourth Tumor Type Evaluated as Part of the 
OGX-427 ORCA™ Program, In Addition to Bladder, Lung and Prostate Cancers 
BOTHELL, Wash. and VANCOUVER, British Columbia, May 1, 2013 /CNW/ - OncoGenex 
Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation 
of the Rainier™ trial, an investigator-sponsored, randomized, 
placebo-controlled Phase 2 trial evaluating OGX-427 in combination with 
ABRAXANE(®) (paclitaxel protein-bound particles for injectable 
suspension)(albumin-bound) and gemcitabine in patients with previously 
untreated metastatic pancreatic cancer. 
Rainier will randomize approximately 130 patients to receive either OGX-427 or 
placebo in combination with ABRAXANE and gemcitabine therapy. The primary 
endpoint of the trial will be overall survival, with additional analyses to 
evaluate progression-free survival (PFS), tumor response rates, safety, 
tolerability, and the effect of therapy on heat shock protein (Hsp27) levels. 
"Based on the positive survival results demonstrated by the Phase 3 MPACT 
(Metastatic Pancreatic Adenocarcinoma Clinical Trial) trial, many patients 
with advanced pancreatic cancer will undoubtedly receive treatment with 
gemcitabine plus ABRAXANE in the future. However, survival times remain short 
for these patients, and we need to continue to explore new strategies to 
address treatment resistance," stated Andrew H. Ko MD, Associate Professor of 
Medicine, Division of Hematology/Oncology at the University of California, San 
Francisco, and a primary investigator on the trial. "The Rainier trial 
provides us the opportunity to explore the role of Hsp27 in pancreatic cancer, 
and the potential ability of OGX-427 to improve on clinical outcomes when 
added to combination chemotherapy." 
The trial is being sponsored by the Sarah Cannon Research Institute (SCRI) and 
will be conducted at approximately 12 sites in the United States. Dr. Andrew 
H. Ko from the University of California, San Francisco, and Dr. Johanna 
Bendell, Director, GI Cancer Research Program at SCRI, will serve as the 
primary investigators on the trial. "We are very excited to bring this trial 
of an exciting novel agent to patients with metastatic pancreatic cancer, who 
desperately need more treatment options," said Dr. Bendell. 
ABOUT PANCREATIC CANCER Pancreatic cancer accounts for approximately 279,000 
new cases each year worldwide. In the United States, an estimated 45,000 
people will be diagnosed with pancreatic cancer and approximately 38,500 will 
die from the disease in 2013. Most pancreatic cancer patients will die within 
the first year of diagnosis, and five-year survival rates are only about 6 
percent. An estimated 85 to 90 percent of patients present with locally 
advanced or metastatic disease. Median five-year survival for patients 
diagnosed with stage IV disease is just 4.5 months, demonstrating the need for 
new therapies with improved efficacy. 
ABOUT OGX-427 and ORCA™ OGX-427 is a once-weekly intravenous (IV) drug that 
is designed to inhibit production of heat shock protein (Hsp27) to disable 
cancer cells' defenses and overcome treatment resistance. Hsp27 is an 
intracellular protein that protects cancer cells by helping them survive, 
leading to resistance and more aggressive cancer phenotypes. 
The ORCA (Ongoing Studies Evaluating Treatment Resistance in CAncer) program 
encompasses clinical trials of OGX-427. Phase 2 clinical trials are underway 
in bladder, lung, pancreatic and prostate cancers, with additional updates to 
the ORCA program expected to be provided later this year. For more information 
on OGX-427 and ORCA, please visit www.OncoGenex.com. 
ABOUT ONCOGENEX OncoGenex is a biopharmaceutical company committed to the 
development and commercialization of new therapies that address treatment 
resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with 
each product candidate having a distinct mechanism of action and representing 
a unique opportunity for cancer drug development. OncoGenex and Teva 
Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global 
collaboration and license agreement to develop and commercialize OncoGenex' 
lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical 
development as a treatment in men with metastatic castrate-resistant prostate 
cancer and in patients with advanced, unresectable non-small cell lung cancer. 
OGX-427 is in Phase 2 clinical development and OGX-225 is currently in 
pre-clinical development. More information is available at www.OncoGenex.com. 
ABOUT SCRI Sarah Cannon Research Institute (SCRI) is a global strategic 
research organization focusing on advancing therapies for patients. It is one 
of the largest clinical research programs, conducting community-based clinical 
trials in oncology and cardiology through affiliations with a network of more 
than 700 physicians in the United States and United Kingdom. Additionally, 
SCRI offers management, regulatory and other research support services to drug 
development sponsors and strategic investigator sites. For more information, 
please visit sarahcannonresearch.com. 
OncoGenex' Forward Looking Statements  This press release contains 
forward-looking statements within the meaning of the "safe harbor" provisions 
of the Private Securities Litigation Reform Act of 1995, including, but not 
limited to, statements concerning our anticipated product development 
activities, such as expected clinical trial completion and design and 
statements regarding the potential benefits and potential development of our 
product candidates. All statements other than statements of historical fact 
are statements that could be deemed forward-looking statements. These 
statements are based on management's current expectations and beliefs and are 
subject to a number of risks, uncertainties and assumptions that could cause 
actual results to differ materially from those described in the 
forward-looking statements, including, among others, the risk that our product 
candidates will not demonstrate the hypothesized or expected benefits, the 
risk of delays in our expected clinical trials, the risk that new developments 
in the rapidly evolving cancer therapy landscape require changes in our 
clinical trial plans or limit the potential benefits of our product candidates 
and the other factors described in our risk factors set forth in our filings 
with the Securities and Exchange Commission from time to time, including the 
Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The 
Company undertakes no obligation to update the forward-looking statements 
contained herein or to reflect events or circumstances occurring after the 
date hereof, other than as may be required by applicable law. 
ABRAXANE(®) is a registered trademark of Celgene Corporation. ORCA™ and 
Rainier™ are registered trademarks of OncoGenex Pharmaceuticals, Inc. 
Media: Jaime Welch, jwelch@oncogenex.com, 604-630-5403; Investor Relations: 
Susan Specht, sspecht@oncogenex.com, 425-686-1535 
SOURCE: OncoGenex Pharmaceuticals, Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: OncoGenex Pharmaceuticals, Inc.
ST: British Columbia
-0- May/01/2013 10:31 GMT
Press spacebar to pause and continue. Press esc to stop.